Mounjaro injection side effects: what the NHS guidance says

Step 1, the first pen: the side effects most people actually notice

The 2.5mg starting pen exists specifically to let your body acclimatise to tirzepatide before any therapeutic dose change. Even so, the days after your first injection are when GI symptoms tend to peak. Nausea is the most common (described by patients as background queasiness rather than acute sickness) followed by loose stools or, for some people, the opposite: constipation and bloating. Burping and indigestion appear frequently in the trial data too.

Fatigue and mild headaches in the first week are also well-documented. Injection-site reactions (a small area of redness, itching or firmness) are generally mild and resolve within a day or two; rotating between your abdomen, thigh and upper arm keeps any one site from becoming irritated. The full side-effect profile for Mounjaro on the NHS covers each of these in more detail, including frequency data from the clinical programme.

Practical things that help: eating smaller portions slowly, staying well-hydrated, and avoiding high-fat or heavily spiced meals in the days around your injection. These are not guaranteed fixes, your prescriber can advise on strategies tailored to you.

Step 2 (dose increases: when side effects can resurface

Tirzepatide is titrated in stages) 2.5mg, then 5mg, 7.5mg and so on, typically in four-week steps, and many people find that each increase brings a brief return of early GI symptoms. This is normal physiology, not a sign that something has gone wrong. The pattern is usually milder than the original response and shorter-lived.

If you're managing a dose increase around a particular week (say, the first week of a new month when you've ordered by payday) build in a few quiet days if you can, particularly for the higher steps. Nausea on an empty stomach is worse; a light meal before injection day is not recommended by the SmPC but eating regularly afterwards helps many people. Always check your maintenance dose schedule against what your prescriber has set, and never adjust timing or dose without speaking to them first.

Dizziness and a faster heartbeat have been reported at higher doses; both are listed in the prescribing information. If dizziness is pronounced or persists, contact your prescriber. For people on medicines affected by slowed gastric emptying (some oral contraceptives, certain antibiotics) your prescriber should know about every drug you take before the prescription is issued. Patient-reported experiences of Mounjaro side effects reflect much of this, with higher doses unsurprisingly generating more reports.

Step 3, when to get medical help without delay

Most Mounjaro side effects are uncomfortable rather than dangerous. A small number are not. The following need prompt medical attention, call 111 or go to A&E if you cannot reach your GP same day:

Severe abdominal pain, especially if it radiates to the back, with or without vomiting. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis as an infrequent but serious risk. The pain pattern described above is the key warning sign. Do not wait for it to pass. The update is indexed on the MHRA Drug Safety Update archive.

Signs of a gallbladder problem (pain in the upper right abdomen, fever, yellowing of skin or eyes) also require urgent assessment. Severe dehydration from persistent vomiting or diarrhoea can damage kidney function; if you cannot keep fluids down for more than a day, get help. Signs of a serious allergic reaction (facial swelling, difficulty breathing, widespread rash) need emergency services immediately. Call 999.

If you're unsure whether a symptom is serious, err on the side of contacting a clinician. That is what the aftercare team at nume is there for, available seven days a week.

Step 4 (reporting side effects and the Yellow Card scheme

The MHRA's Yellow Card scheme lets anyone) patients, carers, healthcare professionals, report a suspected side effect from any medicine, including Mounjaro. Reports help the regulator identify patterns that may not be visible in pre-approval trials. Tirzepatide carries a Black Triangle (▼) designation, meaning it is under additional monitoring; this makes Yellow Card reports especially valuable right now.

You don't need to be certain a symptom is caused by the medicine to report it. A suspicion is enough. The scheme also accepts reports about counterfeit or suspect medicines, relevant given the MHRA's warnings about fake weight-loss pens circulating online. If you're thinking about sourcing Mounjaro, verifying your pharmacy on the GPhC register before ordering is the single most useful check you can do. At nume, every prescription comes from a GPhC-registered pharmacy, premises number 9012878, verifiable at pharmacyregulation.org.

Our prescribers go through side-effect likelihood, your personal medical history and any medicines you already take as a standard part of every consultation, and if you'd like to understand how to get the Mounjaro injection through that process, the steps are straightforward. If you're also weighing up whether the Mounjaro injection is available on the NHS for your situation, that page sets out the current criteria clearly. If that conversation sounds useful, start your free consultation and a real clinician will review your case the same day.